Go Pro
→ Elon just created his own power grid — here’s what’s next (From Banyan Hill Publishing) (Ad)tc pixel Free ESLAW Stock Alerts

Estrella Immunopharma (ESLAW) Competitors

Estrella Immunopharma logo
$0.08 +0.00 (+4.00%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ESLAW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Alvotech?

Estrella Immunopharma (NASDAQ:ESLAW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Alvotech had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.87 beat Alvotech's score of 1.40 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Alvotech Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to Apollomics?

Estrella Immunopharma (NASDAQ:ESLAW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Apollomics N/A N/A N/A

In the previous week, Estrella Immunopharma's average media sentiment score of 1.87 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Apollomics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats Estrella Immunopharma on 1 of the 1 factors compared between the two stocks.

How does Estrella Immunopharma compare to Aravive?

Estrella Immunopharma (NASDAQ:ESLAW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Estrella Immunopharma's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Aravive N/A N/A N/A

Summary

Aravive beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to bioAffinity Technologies?

Estrella Immunopharma (NASDAQ:ESLAW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, bioAffinity Technologies had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.87 beat bioAffinity Technologies' score of -0.14 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
bioAffinity Technologies Neutral

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Summary

bioAffinity Technologies beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to BioVie?

BioVie (NASDAQ:BIVIW) and Estrella Immunopharma (NASDAQ:ESLAW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

In the previous week, BioVie had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.87 beat BioVie's score of 0.29 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Neutral
Estrella Immunopharma Very Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

Summary

BioVie and Estrella Immunopharma tied by winning 1 of the 2 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLAW vs. The Competition

Export
MetricEstrella ImmunopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.01B$7.22B$12.70B
Dividend YieldN/A3.61%2.54%11.69%
P/E RatioN/A12.29273.2025.02
Price / SalesN/A1,293.24601.6377.84
Price / CashN/A106.6377.2052.85
Price / BookN/A16.1912.836.09
Net IncomeN/A-$22.72M$3.47B$348.86M
7 Day PerformanceN/A-1.26%-0.23%-1.62%
1 Month PerformanceN/A12.70%8.05%3.64%
1 Year PerformanceN/A53.58%24.98%14.97%

Estrella Immunopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLAW
Estrella Immunopharma
N/A$0.08
+4.0%		N/AN/A$0.00N/AN/AN/A
ALVOW
Alvotech
N/A$0.38
flat		N/AN/A$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-2.1%		N/A+76.9%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.08
flat		N/AN/A$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ESLAW) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Elon just created his own power grid — here’s what’s next
Elon Musk built the largest private power network in American industry history in just 122 days, using a techn...
Banyan Hill Publishing | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...
Stansberry Research | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel